Trial Profile

A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Apr 2023 ). Final survival analyses and updated results , published in the Journal of Clinical Oncology
12 Oct 2017 Results of pooled data from two phase 3 trial ( A6181034 and Axis trial ) assessing important group differences on the functional assessment of cancer therapy-kidney symptom index disease-related symptoms in patients with metastatic renal cell carcinoma, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
06 Jun 2017 Results (n=373) of retrospective analysis of this study to provide outcomes benchmarks for current and future clinical trials interpretation presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com